Roche Holding AG
- Country
- šØšSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Clinical Trials
2.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1739 trials with phase data)ā¢ Click on a phase to view related trials
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT07200375
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Conditions
- Alzheimers Disease
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13000
- Registration Number
- NCT07177352
- Locations
- šŗšø
Sun Valley Research Center, Inc., Imperial, California, United States
šŗšøInglewood Clinicals, Inglewood, California, United States
šŗšøIrvine Center for Clinical Research, Irvine, California, United States
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
- Conditions
- Antiphospholipid Syndrome
- Interventions
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT07172022
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 900
- Registration Number
- NCT07174310
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 800
- Registration Number
- NCT07169578
- Locations
- šŗšø
Irvine Center for Clinical Research, Irvine, California, United States
šŗšøBasil Clinical, Laurelton, New York, United States
šØš¦Toronto Memory Program, Toronto, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 409
- Next
News
Henlius Biotech in Advanced Licensing Talks with J&J and Roche for Experimental Cancer Drug
Shanghai Henlius Biotech is negotiating with pharmaceutical giants Johnson & Johnson and Roche to sell rights to an experimental cancer drug.
HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies
DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Over 220 Pipeline Therapies in Development for Non-Hodgkin's Lymphoma, Reports DelveInsight
DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
Expert Insights: Navigating the Complex Landscape of Biosimilars and Biobetters Development
Biosimilars must demonstrate close similarity to reference products in quality, non-clinical, and clinical data, while biobetters are purposely differentiated to deliver improvements over originators.
Roche to Challenge Illumina's Dominance with Novel Sequencing Technology Launch in 2024
Roche Holding AG announces plans to introduce innovative sequencing by expansion technology in 2024, potentially disrupting Illumina's long-standing market leadership in next-generation sequencing.
Breakthrough Therapy Designations Driving Pharmaceutical Market to Reach $287.5 Billion by 2029
ā¢ The global market for breakthrough therapies is projected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, representing a compound annual growth rate of 13.8%. ā¢ Expedited regulatory pathways, including the FDA's Breakthrough Therapy Designation and EMA's PRIME scheme, are accelerating development of innovative treatments for serious conditions like cancer and cardiovascular disease. ā¢ Recent success stories include AbbVie's epcoritamab for follicular lymphoma and Merck's sotatercept-csrk (WINREVAIR) for pulmonary arterial hypertension, both receiving breakthrough designations.
Lupus Nephritis Clinical Trial Landscape Shows Active Development
The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.
Global Biotechnology Market Projected to Reach USD 3.54 Trillion by 2033, Driven by Therapeutic Innovations
The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.